Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $933.51M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.86M
Average 1.00M
Returns on capital
Nektar Therapeutics management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-182.6%
avg -213.3%
ROIC
-52.8%
avg -24.4%
ROA
-58.5%
avg -31.6%
Analysis
ROIC is currently the strongest return metric at -52.8% versus its period average of -24.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Howard W. Robin | Chief Executive Officer, President & Director | USD 2.33M | 73 | 54.63K | 0.28% |
Jonathan Zalevsky | Senior Vice President and Chief Research & Development Officer | USD 1.19M | 51 | 9.57K | 0.05% |
Linda Rubinstein | Chief Financial Officer and Principal Financial & Accounting Officer | USD 460.85K | 59 | — | — |
Ken Franke | Senior Vice President of Biologics Process Development & Manufacturing | — | — | — | — |
Mary Tagliaferri | Chief Medical Officer | — | 60 | — | — |
Spilios Asimakopoulos | Vice President of Commercial Strategy & Marketing | — | — | — | — |
Elizabeth Zhang | VP of Legal, Corporate Counsel & Secretary | — | — | — | — |
Jennifer Ruddock | Chief Business Officer | — | — | — | — |
Robert Bacci | Chief People Officer and Head of Quality & Facilities | — | — | — | — |
Jason Barnard | Chief Accounting Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$2.43M
Net Transaction Value
−$2.43M
Net selling
Most Active
ROBIN HOWARD W
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 18, 26Aug 18, 2026 | Zalevsky Jonathan Direct | Sell | $13.4K$13,388.28 |
| Aug 18, 26Aug 18, 2026 | ROBIN HOWARD W Direct | Sell | $30.1K$30,087.64 |
| Jun 30, 26Jun 30, 2026 | Zalevsky Jonathan Direct | Sell | $397.7K$397,670.00 |
| Jun 17, 26Jun 17, 2026 | ROBIN HOWARD W Direct | Sell | $334.5K$334,455.00 |
| Jun 17, 26Jun 17, 2026 | ROBIN HOWARD W Direct | Sell | $277.4K$277,425.00 |
| Jun 16, 26Jun 16, 2026 | ROBIN HOWARD W Direct | Sell | $318K$318,020.91 |
| Jun 16, 26Jun 16, 2026 | ROBIN HOWARD W Direct | Sell | $285.2K$285,154.87 |
| Jun 15, 26Jun 15, 2026 | Zalevsky Jonathan Direct | Sell | $336.2K$336,211.98 |
| May 19, 26May 19, 2026 | Zalevsky Jonathan Direct | Sell | $13K$13,036.49 |
| May 19, 26May 19, 2026 | ROBIN HOWARD W Direct | Sell | $29.1K$29,086.44 |
1–10 of 16
Summary
Insiders reported 0 buys worth $0.00 and 16 sells worth $2.43M over the last 12 months. That adds up to net selling of $2.43M. ROBIN HOWARD W was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A11 analysts |
| Revenue | N/A | N/A | -15.7% | +27.4% (5yr)12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | N/A | N/A12 analysts |
Analysis
Recent growth has been strongest in Revenue at -15.7% over three years. Forward estimates point to Revenue at +27.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Nektar Therapeutics compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about NKTR's management, answered from reported figures.
Who manages NKTR?
Nektar Therapeutics (NKTR) lists 10 active executives. The top listed executive is Ken Franke, Senior Vice President of Biologics Process Development & Manufacturing.
Are NKTR insiders buying or selling?
Recent insider activity shows net buying of $34.74M.
Continue the stock analysis
Jump to another research area for this company.